GlassScriptPhysician profile
Paul Moyer
NPI 1629097126
$453.86
in general payments reported to CMS, 2019-2025
11 companies · $59.66 in 2025
The $59.66 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.63 · 2022: $153 · 2023: $117 · 2024: $92.16 · 2025: $59.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.79 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $118.38 | 2022-2025 | Clareon, Hydrus Microstent, Simbrinza |
| Thea Pharma INC. | $60.47 | 2024-2025 | Iyuzeh |
| Carl Zeiss Meditec, INC. | $60.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $40.54 | 2022-2023 | Cequa |
| Abbvie INC. | $38.34 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $37.55 | 2023 | Vyzulta, Miebo |
| Eyevance Pharmaceuticals LLC | $31.22 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.52 | 2021 | |
| Ocular Therapeutix, INC. | $18.45 | 2024 | Dextenza |
| Biotissue Holdings INC. | $16.28 | 2024 | |
| Allergan, INC. | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Moyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.